Article thumbnail

Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series

By Øystein Fluge and Olav Mella
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2711959
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). Amino N: Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome.
  2. (2002). Antinuclear autoantibodies (ANA) in Gulf War-related illness and chronic fatigue syndrome (CFS) patients. Clin Exp Immunol
  3. (2006). B cell targeted therapies: safety considerations. J Rheumatol Suppl
  4. (1997). BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol
  5. (2006). Bleijenberg G: Chronic fatigue syndrome. Lancet
  6. (1991). Brincker H: MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta Oncol
  7. (2005). Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol
  8. (2006). Chronic fatigue syndrome.
  9. (1996). EM: Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.
  10. (1997). EM: High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome. Arthritis Rheum
  11. (2006). G: A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. Qjm
  12. (2008). Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome.
  13. (2004). JT: IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In Vivo
  14. (2002). JT: IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo
  15. (2007). JT: Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo
  16. (1994). Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study.
  17. (2005). Komaroff AL: Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol
  18. (2007). Koneru AO: Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr Rheumatol Rep
  19. (2006). MJ: B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol
  20. (2002). NM: Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol
  21. (2004). Peakman M: High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol
  22. (1987). Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.
  23. (2006). Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum
  24. (2005). Reeves WC: Evaluation of autoantibodies to common and neuronal cell antigens in Chronic Fatigue Syndrome. J Autoimmune Dis
  25. (2009). Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev
  26. (2007). Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
  27. (2007). Rituximab therapy in malignant lymphoma. Oncogene
  28. (2008). St Clair EW, Tedder TF: B-lymphocyte contributions to human autoimmune disease. Immunol Rev
  29. (2004). T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
  30. (2008). Toubi E: Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol
  31. (2004). Valagussa P: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.